Psoriasismanaging psychNCT07615257
Managing Psychological Distress Through Mindfulness-based CBT to Evaluate Its Effectiveness on Self-compassion Among Psoriasis Patients:The Mediating Role of Mental Health Locus of Control
A study testing Mindfulness-Based Cognitive Therapy (MBCT) in people with Psoriasis, run by Islamia University of Bahawalpur at 1 site in Pakistan.
Trial summary
Your research study is about evaluating the effectiveness of Mindfulness-Based Cognitive Therapy (MBCT) in reducing psychological distress among psoriasis patients and improving their self-compassion and Mental Health Locus of Control (MHLC). Read more about this study
- Who is it for?
- Ages 25 to 75 years
- Conditions the study is for
- Psoriasis
- What is being tested?
- Mindfulness-Based Cognitive Therapy (MBCT)
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 128 participants
- Where
- 1 sitePakistan
- Study dates
- 5 Feb 2025to 12 Dec 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 25 to 75 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Diagnosed psoriasis patients
- Age between 18 and 65 years
- Both male and female participants
- Participants willing to provide informed consent
- Participants experiencing psychological distress
Who cannot join
- Under the age of 18 years will be excluded.
- Patients with severe psychiatric disorders
- Patients currently receiving other psychological therapies
- Patients with serious medical or neurological conditions
- Participants unwilling to continue the intervention sessions
- Patients with cognitive impairment affecting participation
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Pakistan1 site, 1 recruiting
- Recruiting
Department of Dermatologist Sheikh Zayed Hospital Rahim Yar Khan
Rahim Yar Khan, Punjab Province, 64200
Arslan Khalid, Assistant Professor IUB, 923006700809, arslan.khalid@iub.edu.pk
About this study
Your research study is about evaluating the effectiveness of Mindfulness-Based Cognitive Therapy (MBCT) in reducing psychological distress among psoriasis patients and improving their self-compassion and Mental Health Locus of Control (MHLC).
The study highlights that psoriasis patients often suffer not only from physical symptoms but also from psychological problems such as stress, anxiety, depression, self-judgment, and low self-compassion. Traditional treatments mainly focus on physical symptoms and may not fully address these emotional and psychological difficulties.
Read more
To address this gap, the study proposes MBCT as a psychological intervention that combines mindfulness practices with cognitive therapy techniques. MBCT helps patients become more self-aware, reduce negative thinking, and develop self-compassion without self-judgment. The research also explores MHLC, which refers to how much control individuals believe they have over their health outcomes.
The study aims to investigate whether MBCT can:
- Reduce psychological distress, anxiety, depression, and stress levels
- Improve self-compassion among psoriasis patients
- Shift patients' locus of control from external to internal
- Enhance emotional well-being and coping mechanisms
The research follows a quantitative experimental design conducted in phases. Initially, baseline levels of distress, MHLC, and self-compassion will be assessed. Later, MBCT interventions will be implemented and evaluated for effectiveness.
Overall, the study seeks to contribute to integrated psoriasis care by emphasizing the importance of psychological health alongside physical treatment, ultimately improving patients' quality of life and therapeutic outcomes.
- Conditions
- Psoriasis
- Being tested
- Mindfulness-Based Cognitive Therapy (MBCT), Usual Care
- Medical subject headings
- Psoriasis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Mindfulness-Based Cognitive Therapy (MBCT)Behavioural
Mindfulness-Based Cognitive Therapy (MBCT) will be administered to psoriasis patients to reduce psychological distress and improve self-compassion and mental health locus of control. The intervention includes mindfulness practices and cognitive behavioral techniques delivered in structured sessions.
Usual CareOther
Participants in the control group will receive usual care without Mindfulness-Based Cognitive Therapy intervention.
| Study group | Role | What they receive |
|---|---|---|
| Experimental Group | Experimental | Participants in this group will receive Mindfulness-Based Cognitive Therapy (MBCT) intervention. Receives: Behavioral: Mindfulness-Based Cognitive Therapy (MBCT) |
| Control Group | Experimental | Participants in this group will receive usual care without MBCT intervention. Receives: Other: Usual Care |
What is being measured
The primary outcome is the main question the study is designed to answer.
Reduction in Psychological Distress
To evaluate the effectiveness of Mindfulness-Based Cognitive Therapy (MBCT) in reducing psychological distress among psoriasis patients.
Measured: 12 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted29 May 2026
- Study start5 Feb 2025
- Primary completion1 Nov 2026 (estimated)
- Study completion12 Dec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for PsoriasisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Health services research
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 128 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Islamia University of Bahawalpur
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Rafia Ghaffar, Islamia University of Bahawalpur
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07615257
- Sponsor's protocol ID
- 403/ub/szmc/szh
- Other IDs
- ref no 403/ub/szmc/szh
- Acronym
- managing psych
- Status last verified
- May 2026
- First submitted
- 22 May 2026
- Last updated
- 29 May 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 29 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Managing Psychological Distress Through Mindfulness-based CBT to Evaluate Its Effectiveness on Self-compassion Among Psoriasis Patients:The Mediating Role of Mental Health Locus of Control
- ClinicalTrials.gov ID
- NCT07615257
- Acronym / sponsor ID
- managing psych / 403/ub/szmc/szh
- Conditions
- Psoriasis
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 128 participants (estimated)
- Lead sponsor
- Islamia University of BahawalpurUniversity, hospital or other
- Study start
- 5 Feb 2025 (actual)
- Primary completion
- 1 Nov 2026 (estimated)
- Study completion
- 12 Dec 2026 (estimated)
- First posted
- 29 May 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Your research study is about evaluating the effectiveness of Mindfulness-Based Cognitive Therapy (MBCT) in reducing psychological distress among psoriasis patients and improving their self-compassion and Mental Health Locus of Control (MHLC).
The study highlights that psoriasis patients often suffer not only from physical symptoms but also from psychological problems such as stress, anxiety, depression, self-judgment, and low self-compassion. Traditional treatments mainly focus on physical symptoms and may not fully address these emotional and psychological difficulties.
To address this gap, the study proposes MBCT as a psychological intervention that combines mindfulness practices with cognitive therapy techniques. MBCT helps patients become more self-aware, reduce negative thinking, and develop self-compassion without self-judgment. The research also explores MHLC, which refers to how much control individuals believe they have over their health outcomes.
The study aims to investigate whether MBCT can:
- Reduce psychological distress, anxiety, depression, and stress levels
- Improve self-compassion among psoriasis patients
- Shift patients' locus of control from external to internal
- Enhance emotional well-being and coping mechanisms
The research follows a quantitative experimental design conducted in phases. Initially, baseline levels of distress, MHLC, and self-compassion will be assessed. Later, MBCT interventions will be implemented and evaluated for effectiveness.
Overall, the study seeks to contribute to integrated psoriasis care by emphasizing the importance of psychological health alongside physical treatment, ultimately improving patients' quality of life and therapeutic outcomes.
Study design
- Primary purpose
- Health services research
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (participant)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Experimental Group | Experimental | Behavioral: Mindfulness-Based Cognitive Therapy (MBCT)Participants in this group will receive Mindfulness-Based Cognitive Therapy (MBCT) intervention. |
| Control Group | Experimental | Other: Usual CareParticipants in this group will receive usual care without MBCT intervention. |
Who may qualify
- Ages
- 25 to 75 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Diagnosed psoriasis patients
- Age between 18 and 65 years
- Both male and female participants
- Participants willing to provide informed consent
- Participants experiencing psychological distress
Key exclusion criteria (6 listed)
- Under the age of 18 years will be excluded.
- Patients with severe psychiatric disorders
- Patients currently receiving other psychological therapies
- Patients with serious medical or neurological conditions
- Participants unwilling to continue the intervention sessions
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Mindfulness-Based Cognitive Therapy (MBCT)Mindfulness-Based Cognitive Therapy (MBCT) will be administered to psoriasis patients to reduce psychological distress and improve self-compassion and mental health locus of control. The intervention includes mindfulness practices and cognitive behavioral techniques delivered in structured sessions. | Behavioural | Experimental Group |
| Usual CareParticipants in the control group will receive usual care without Mindfulness-Based Cognitive Therapy intervention. | Other | Control Group |
Primary outcome
Reduction in Psychological Distress
Time frame: 12 weeks
To evaluate the effectiveness of Mindfulness-Based Cognitive Therapy (MBCT) in reducing psychological distress among psoriasis patients.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 29 May 2026.
Related trials for Psoriasis
Active, not recruitingObservational study
Deucravacitinib for Patients With Moderate/Severe Psoriasis: A Real-Life Experience in Italy
Psoriasis
Not yet recruitingPhase 1
Comparing the Extent to Which Apremilast is Made Available in the Body After Administration as an Extended-release or Immediate-release Formulation
Psoriasis, Arthritis, Psoriatic
Active, not recruitingPhase 1
Safety and Pharmacokinetics of LPX-TI641 in Rheumatoid Arthritis and Psoriatic Arthritis
Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA)
RecruitingPhase 1
A Study of HL40626S Tablets in Healthy Adults
Skin Disease, Immune System Disease
RecruitingObservational study
Metabolic Profiling of Immune Responses in Immune-mediated Diseases
Primary Immunodeficiency, Psoriasis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Mindfulness-Based Cognitive Therapy (MBCT) in people with Psoriasis, run by Islamia University of Bahawalpur at 1 site in Pakistan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 29 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Pakistan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Rafia Ghaffar, Phd (923336096376, rafiaghaffar1@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Reduction in Psychological Distress (time frame: 12 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 May 2026.